HUMAW

Insider Trades

Name	Value	Action	Price	Current Price
Sebelius KathleenDirector $50k56.8k shares BuyMay 19, 2026 $0.88 --
Parikh Shamik JChief Medical Officer $41k45.9k shares SellMay 18, 2026 $0.8967 --
Sander Dale A.CFO And Chief Corp. Dev. Off $41k45.9k shares SellMay 18, 2026 $0.8967 --
Constantino Michael T.Director $9.8k11k shares BuyMay 18, 2026 $0.8945 --
Dougan Brady WDirector $935k591.7k shares SellAug 20, 2025 $1.58 --
Niklason Laura EDirector, Officer: President, CEO And Director $935k591.7k shares SellAug 20, 2025 $1.58 --

Trade HUMAW

About Humacyte, Inc.

Humacyte, Inc. is a company dedicated to the creation and production of bioengineered human tissues that are readily available and suitable for implantation. These advanced tissues are intended for the treatment of a variety of diseases and medical conditions, applicable to numerous anatomical sites and therapeutic areas. The company employs its distinct, proprietary scientific platform to engineer and manufacture human acellular vessels (HAVs). A significant advantage of these HAVs is their capacity to be implanted into patients without triggering an adverse immune response or leading to rejection by the body. Humacyte is actively developing a diverse portfolio of HAVs, aiming to address needs within the vascular repair, reconstruction, and replacement market. This encompasses uses in cases of vascular trauma, establishing arteriovenous access for hemodialysis, treating peripheral arterial disease, performing pediatric heart surgery, and executing coronary artery bypass grafting. Additionally, their technology supports the delivery of cellular therapies, such as pancreatic islet cell transplantation for managing Type 1 diabetes. Established in 2004, Humacyte, Inc. is headquartered in Durham, North Carolina.

CEO: Laura E. Niklason
IPO Date: Dec 1, 2020

Market Data

Open: $0.23
High: $0.23
Low: $0.002
Volume: 68.4K
Avg Volume: 18.6K
52W High: $0.23
52W Low: $0.002

Valuation

Market Cap: $8.4M
Enterprise Value: $173M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-106M
Revenue: $2.0M
Net Income: $-41M
Cash: $50M
Debt: $65M

Events

EarningsAug 17

EPS est. -0.098